Der blev foretaget to kliniske forsøg med Privigen, et med patienter med primær immundefekt (PID) og et med patienter med immun trombocytopenisk purpura (ITP).
Two clinical studies with Privigen were performed, one in patients with primary immunodeficiency (PID) and one in patients with immune thrombocytopenic purpura (ITP).